辽宁成大生物股份有限公司 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/19 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 月 6 | 6 | 19 | 日~2026 | 年 | 月 | 18 | 日 | | 预计回购金额 | 万元~2,000 1,000 | | | 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 股 384,899 | | | | | | | | | 累计已回购股数占总股本比例 | 0.092% | | | | ...

Investment Rating - The industry rating is maintained at "Overweight" [2] Core Insights - The vaccine industry is currently facing short-term performance pressure due to weak demand and structural oversupply, with many companies experiencing declines or losses in performance [1][7][8] - Despite the challenges, innovation and international expansion are ongoing, providing potential for medium to long-term growth [1][8] - The industry is transitioning from scale expansion to innovation-driven growth, with policy, demand, and technology as the three main driving factors for development [8][24][26] Summary by Sections Domestic and International Vaccine Dynamics - Kanghua Biotech has initiated Phase I clinical trials for its six-valent norovirus vaccine, which theoretically can prevent over 90% of norovirus infections [1] - Wantai Biopharma's bivalent HPV vaccine has successfully passed the WHO PQ periodic review [1] - Zhifei Biological's application for clinical trials of a freeze-dried inactivated vaccine for Japanese encephalitis has been accepted [1] Performance Forecasts - Chengda Bio expects a 59.34%-63.98% decrease in net profit for 2025 compared to the previous year [1] - CanSino anticipates a revenue increase of 22.88%-27.61% for 2025, with a turnaround in net profit [1] - Watson Bio forecasts a revenue of 2.4-2.43 billion yuan for 2025, a decline of approximately 14.9%-13.9% [1] - Other companies like Kangtai Bio and Wantai Bio also expect significant declines in net profit for 2025 [1] Market Performance - The vaccine sector saw a decline of 1.65% last week, with the overall pharmaceutical industry down 3.31% [2][5] - The vaccine sector has experienced a cumulative decline of 10.08% since the beginning of 2025 [5][13] Valuation Metrics - The vaccine sector's PE (ttm) is 92.01X, down 1.88X from the previous week, while the PB (lf) is 1.78X, down 0.04X [6] - The PE is at the 55.99% percentile since 2013, and the PB is at the 1.28% percentile since 2013 [6] Investment Recommendations - The vaccine industry is still under pressure, but companies are actively adjusting their pipeline strategies, focusing on technological innovation and multi-valent products [7][8] - Long-term prospects remain positive due to innovation and international market expansion, with a recommendation to focus on companies with strong R&D capabilities and differentiated product offerings, such as CanSino [8][26]

已有两家人用狂犬病疫苗企业业绩预降。 根据中国疾控数据，2025年全国狂犬病报告发病244例、死亡233例，两项数字均创2020年以来新高。伴 随着狂犬病发病数量抬头，人用狂犬病疫苗企业的业绩却在走低，这是为何？ 11月26日晚间，国内人用狂犬病疫苗最大厂家成大生物（688739.SH）发布的年报预告显示，2025年业 绩出现腰斩。 成大生物预计2025年年度实现归属于母公司所有者的净利润为1.23亿元至1.39亿元，同比减少59.34%至 63.98%。 无独有偶，另外一家人用狂犬病疫苗企业康华生物（300841.SZ）近日发布的年报业绩预告显示，公司 预计2025年归属于上市公司股东的净利润将同比减少41.55%至52.09%。 狂犬病是由狂犬病病毒感染所致的一种人兽共患病，是《中华人民共和国传染病防治法》规定的一种乙 类传染病，是迄今为止人类病死率最高的急性传染病。狂犬病一旦发病，死亡率几乎为100%，目前还 缺乏有效的治疗方法，因此，控制狂犬病疫情的主要手段就是接种疫苗。 狂犬病疫苗分为人用狂犬病疫苗和兽用狂犬病疫苗两种，中国使用最广的是人用狂犬病疫苗。 对于业绩下滑，成大生物与康华生物均提及受行业监 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 第七十五条 本规则所称"以上""内"含本数；"过""低于""不足""多于"不含本数。 第七十六条 本规则所称公告、通知或股东会补充通知，是指在符合中国证监会规定条件的媒体和上海 证券交易所网站上公布有关信息披露内容。 第七十七条 本规则为《公司章程》附则。本规则未尽事宜，或者与有关法律、法规、规范性文件的强 制性规定或《公司章程》的要求相抵触的，按有关法律、法规、规范性文件、《公司章程》的规定执 行。 第七十八条 本规则的解释权属于董事会。 第七十九条 本规则由董事会制定、经股东会批准之日起生效，修改时亦同。 辽宁成大生物股份有限公司 董事会 2026年 1月26日 证券代码：688739 证券简称：成大生物 公告编号：2026-004 辽宁成大生物股份有限公司 2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （三）本次业绩预告未经注册会计师审 ...

Performance Reports - Company Kexin New Energy (300731.SZ) expects a net profit of 30 million to 40 million yuan in 2025, representing a year-on-year growth of 73.62% to 131.49% due to the promotion of new battery applications [2] - Company AVIC Chengfei (302132.SZ) anticipates a net profit of 3.4 billion to 3.6 billion yuan in 2025, reflecting a growth of 5.47% to 11.67% compared to the previous year [2] - Company ST Jinggu (600265.SH) projects a revenue of 175 million to 205 million yuan in 2025, with a net loss of 265 million to 215 million yuan, potentially triggering delisting risk [2] - Company Yijiahe (603666.SH) expects a net loss of 35 million to 24 million yuan in 2025, an improvement from a loss of 218 million yuan in the previous year [3] - Company Guoke Micro (300672.SZ) forecasts a net loss of 180 million to 250 million yuan in 2025, a significant decline from a profit of 97.15 million yuan in the previous year [3] - Company Xinbeiyang (002376.SZ) anticipates a net profit of 70 million to 80 million yuan in 2025, a year-on-year increase of 44% to 65% driven by growth in smart logistics equipment [3] - Company Tianyue Advanced (688234.SH) expects a net loss of 185 million to 225 million yuan in 2025 due to increased costs and decreased market prices [4] - Company Jieshun Technology (002609.SZ) projects a net profit of 55 million to 75 million yuan in 2025, representing a growth of 75.23% to 138.96% [4] - Company Lante Optics (688127.SH) expects a net profit of 375 million to 400 million yuan in 2025, a growth of 70.04% to 81.38% [5] - Company Duofuduo (002407.SZ) anticipates a net profit of 200 million to 280 million yuan in 2025, recovering from a loss of 30.8 million yuan in the previous year [5] - Company Efort (688165.SH) expects a net loss of 450 million to 550 million yuan in 2025, with losses expected to widen significantly [5] - Company Pulit (002324.SZ) forecasts a net profit of 361 million to 416 million yuan in 2025, a year-on-year increase of 155.76% to 194.73% [6] - Company Jinchun Co. (300877.SZ) expects a net profit of 82 million to 88 million yuan in 2025, a growth of 165.04% to 184.43% [6] - Company Huahai Pharmaceutical (600521.SH) anticipates a net profit of 224 million to 335 million yuan in 2025, a decline of 70% to 80% [6] Orders and Investments - Company Dinglong Co. (300054.SZ) plans to acquire 70% of Shenzhen Haofei New Materials Co. for 630 million yuan, with a total valuation of 900 million yuan [7] - Company Chuanhuan Technology (300547.SZ) intends to invest approximately 1.1 billion yuan to establish a manufacturing headquarters in Anhui [7] - Company Mongcao Ecological (300355.SZ) has terminated a PPP project agreement, with a total project cost of 83.87 million yuan [7] - Company Fengfan Co. (601700.SH) plans to acquire 51% of Beijing Yanling Jiaye Intelligent Technology Co. for 383 million yuan [8] - Company Haowei Group (603501.SH) intends to invest up to 50 million USD in AI chip supplier Aixin Yuanzhi [8] - Company Chengda Bio (688739.SH) plans to establish a wholly-owned subsidiary with an investment of 1 billion yuan focused on innovative drug development [8] - Company Chengda Bio (688739.SH) is also setting up a pharmaceutical investment fund with a total scale of up to 1 billion yuan [9] - Company Efort (688165.SH) is planning to acquire shares of Shanghai Shengpu Fluid Equipment Co. through a combination of cash and stock [9] Major Shareholder Changes - Company Tongfu Microelectronics (002156.SZ) reports that its controlling shareholder has reduced its stake by 15 million shares, decreasing its holding from 19.79% to 18.80% [10] Listing on Beijing Stock Exchange - Company Xiamen Tungsten (600549.SH) announces that its subsidiary Jinlong Rare Earth is applying for public stock issuance and listing on the Beijing Stock Exchange [11]

（文章来源：证券日报） 证券日报网讯 1月26日，成大生物发布公告称，公司预计2025年年度实现归属于母公司所有者的净利润 为12，347.00万元至13，939.00万元，与上年同期相比，将减少20，343.16万元至21，935.16万元，同比 减少59.34%至63.98%。 ...

智通财经APP讯，成大生物(688739.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润为1.23亿元至1.39亿元，与上年同期(法定披露数据)相比，将减少20,343.16万元至21,935.16万元， 同比减少59.34%至63.98%。 ...

创新药子公司将作为公司布局创新药领域的核心载体，围绕存在重大未被满足临床需求的疾病领域进行 前瞻性布局，将重点关注免疫抗肿瘤、自身免疫性疾病等方向，并视研发进展及市场环境变化，适时拓 展至心血管、内分泌等其他具有发展潜力的领域。创新药子公司将借鉴行业成熟运营模式，通过自主研 发、产品引进及收购、合资共建、股权投资等多维方式推进创新药管线建设，构建研发、转化、产业化 全链条闭环运营体系，提升公司在创新药领域的专业化投资与市场化运营能力。 格隆汇1月26日丨成大生物(688739.SH)公布，为落实公司疫苗与创新药双轮驱动的长期发展战略，把握 创新生物药领域的发展机遇，公司拟以自有资金10亿元设立创新药子公司，持有其100%股权。为提高 资金使用效率，注册资本将根据业务拓展节奏及研发项目进度分期注入，实现资金投入与项目需求的动 态匹配。该创新药子公司将专注于创新药研发、优质项目引进与并购、核心团队搭建及专业化运营体系 建设，助力公司打造第二增长曲线。 ...

第一条 为进一步加强辽宁成大生物股份有限公司（以下简称"本公司"或 "公司"）的关联交易管理，明确管理职责和分工，维护公司股东和债权人的合 法权益，特别是中小投资者的合法权益，保证公司与关联方之间订立的关联交易 合同符合公平、公开、公正的原则，依据《中华人民共和国公司法》《中华人民 共和国证券法》（以下简称"《证券法》"）《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）《上海证券交易所上市公司自律监管指引 第5号——交易与关联交易》及其他有关法律、法规规定和《辽宁成大生物股份 有限公司章程》（以下简称"《公司章程》"）的规定，制订本制度。 第二条 公司关联交易的决策管理、信息披露等事项，应当遵守本制度。 第三条 公司处理关联交易事项应当遵循下列原则： (一) 符合诚实信用的原则，保证关联交易的合法性、必要性、合理性和公 允性； (二) 公司与关联人之间的关联交易应签订书面协议，协议的签订应遵循平 等、自愿、等价、有偿的原则； 辽宁成大生物股份有限公司 关联交易管理制度 辽宁成大生物股份有限公司 关联交易管理制度 第一章 总 则 (三) 关联董事、关联股东，在就该关联交易相关事项进行表决时，应 ...

辽宁成大生物股份有限公司 章 程 二〇二六年一月 | . . | 4 | | --- | --- | | . | œ | | 第一章 | 总则 2 | | | --- | --- | --- | | 第二章 | 经营宗旨和范围 3 | | | 第三章 | 股份 4 | | | 第一节 | 股份发行 4 | | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 9 | | | 第四章 | 股东和股东会 | 10 | | 第一节 | 股东的一般规定 | 10 | | 第二节 | 控股股东和实际控制人 | 13 | | 第三节 | 股东会的一般规定 | 15 | | 第四节 | 股东会的召集 | 20 | | 第五节 | 股东会的提案与通知 | 21 | | 第六节 | 股东会的召开 | 23 | | 第七节 | 股东会的表决和决议 | 26 | | 第五章 | 董事及董事会 | 30 | | 第一节 | 董事的一般规定 | 30 | | 第二节 | 董事会 33 | | | 第三节 | 独立董事 39 | | | 第四节 | 董事会专门委员会 | 42 | | 第六章 | 高级管理人员 | 4 ...